Griffin Asset Management Inc. Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

Griffin Asset Management Inc. increased its holdings in Novo Nordisk A/S (NYSE:NVOGet Rating) by 28.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,400 shares of the company’s stock after buying an additional 1,400 shares during the quarter. Griffin Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $711,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. First Affirmative Financial Network boosted its holdings in shares of Novo Nordisk A/S by 8.5% in the first quarter. First Affirmative Financial Network now owns 5,146 shares of the company’s stock worth $571,000 after buying an additional 405 shares during the last quarter. First American Trust FSB lifted its holdings in Novo Nordisk A/S by 4.1% during the first quarter. First American Trust FSB now owns 49,448 shares of the company’s stock valued at $5,492,000 after purchasing an additional 1,926 shares in the last quarter. Private Trust Co. NA lifted its holdings in Novo Nordisk A/S by 34.6% during the first quarter. Private Trust Co. NA now owns 3,022 shares of the company’s stock valued at $336,000 after purchasing an additional 776 shares in the last quarter. Ipswich Investment Management Co. Inc. lifted its holdings in Novo Nordisk A/S by 1.4% during the first quarter. Ipswich Investment Management Co. Inc. now owns 52,380 shares of the company’s stock valued at $5,817,000 after purchasing an additional 710 shares in the last quarter. Finally, Veriti Management LLC lifted its holdings in Novo Nordisk A/S by 6.4% during the first quarter. Veriti Management LLC now owns 27,146 shares of the company’s stock valued at $3,015,000 after purchasing an additional 1,626 shares in the last quarter.

Several equities analysts have weighed in on NVO shares. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Novo Nordisk A/S from 850.00 to 900.00 in a report on Wednesday, May 4th. JPMorgan Chase & Co. upgraded shares of Novo Nordisk A/S from a “neutral” rating to an “overweight” rating in a research report on Tuesday, June 7th. StockNews.com began coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Guggenheim upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, May 31st. Finally, Berenberg Bank boosted their target price on shares of Novo Nordisk A/S from 585.00 to 780.00 and gave the company a “hold” rating in a research note on Tuesday, April 19th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $655.40.

NYSE:NVO opened at $107.34 on Thursday. Novo Nordisk A/S has a 1-year low of $81.65 and a 1-year high of $122.16. The company has a 50-day moving average of $109.81 and a 200 day moving average of $107.25. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.36.

Novo Nordisk A/S (NYSE:NVOGet Rating) last released its quarterly earnings data on Friday, April 29th. The company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. Novo Nordisk A/S had a net margin of 33.16% and a return on equity of 72.67%. The company had revenue of $6.34 billion during the quarter, compared to analyst estimates of $5.82 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.52 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile (Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Featured Stories

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOGet Rating).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.